Double-Blind Study of Papaverine Hydrochloride on the Efficacy in the Treatment of Intermittent Claudication

Seino, Yoshihiko; Rose, Harold B.; Kanazawa, Masakuni; Vyden, John K.; Wall, Francis J.
April 1983
Angiology;Apr1983, Vol. 34 Issue 4, p257
Academic Journal
A double-blind, placebo-controlled, parallel groups study design was utilized to evaluate the efficacy and the safety of papaverine HCL (PA, 300-1,500 mg/day) in the treatment of intermittent claudication. The study was in two phases: Phase 1-6 weeks duration with treadmill claudication tests and doppler ankle/brachial pressure studies every 2 weeks to establish disease stability; Phase 11-12 weeks double-blind evaluation of PA versus placebo (PL) with treadmill claudication tests and doppler ankle/brachial pressure studies every 4 weeks. Intermittent claudication was documented by symptoms, history and objective evidence of decreased blood supply to the lower extremities: decreased resting and post-exercise ankle/brachial pressure indices (A/B Pr), diminished segmental pulse-volumes and physical findings. Data were collected to determine the distance to initial pain (IP), rapidly increasing pain (RIP) and absolute claudication (AC) during treadmill tests and also the changes in resting and post-exercise A/B Pr. In 20 patients who completed this study, the distance to RIP was increased 43% by PA and decreased 2% by PL (p=0.012). PA increased the distance to AC by 29%, but was decreased by 1% in PL (p=0.039). The A/B Pr studies showed significant less decrease in 1 minute and 2.5 minutes post exercise A/B Pr at 12 weeks in PA patients as compared to those in PL patients. Compared to PL, significantly greater increases in the key measurements of exercise performance and less decreases in post exercise A/B Pr were developed by the peripheral vasodilator, papaverine HCL. These results indicate that papaverine HCL is a safe and useful adjunct in the medial treatment of peripheral arterial insufficiency.


Related Articles

  • Naftidrofuryl: A Review of its Use in the Treatment of Intermittent Claudication. Goldsmith, David R.; Wellington, Keri // Drugs & Aging;2005, Vol. 22 Issue 11, p967 

    Naftidrofuryl (Praxilene®) is a vasodilator that has been used in the treatment of intermittent claudication for >30 years in Europe to improve walking distance and provide symptomatic relief. However, earlier trials had inconsistencies in design and the clinical relevance of the treatment...

  • Propionyl-l-carnitine for intermittent claudication. Deckert, James // Journal of Family Practice;Jun1997, Vol. 44 Issue 6, p533 

    The article discusses research being done on the effect of propionyl-L-carnitine on the quality of life in intermittent claudication, with reference to a study by G. Brevetti, S. Perna, C. Sabba et al, which appeared in the 1997 issue of the "American Journal of Cardiology." Patients included...

  • Effects of Ethaverine Hydrochloride on the Walking Tolerance of Patients with Intermittent Claudication. Trainor, Frieda S.; Phillips, Raymond E.; Michie, David D.; Zellner, Stephen R.; Hogan, Jr, Leo; Chubb, James M. // Angiology;May1986, Vol. 37 Issue 5, p343 

    The effect of ethaverine hydrochloride on excercise tolerance of patients with intermittent claudication was evaluated in a double-blind, placebo-controlled study conducted at three sites. Forty-five patients with symptoms of occlusive arterial insufficiency of the lower extremities were...

  • CIRCADIAN PERIODICITY OF CALF BLOOD FLOW IN SUBJECTS WITH INTERMITTENT CLAUDICATION. Bartoli, V.; Dorigo, B.; Tedeschi, E.; Biti, G. P.; Voegelin, M. R. // Angiology;Apr1970, Vol. 21 Issue 4, p215 

    The best-fit method was applied to data of calf basal resting and reactive hyperemia blood flow, recorded at 4-hr, intervals during a day in 15 patients with intermittent claudication. The mathematical-statistical analysis suggests existence of a circadian rhythm of calf blood flow, which has...

  • Treatment of intermittent claudication. Karthikeyan, G.; Eikelboom, John W. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/21/2009, p671 

    The authors reflect on methods which are used to treat intermittent claudication. They suggest that any methods that are used should improve the patient's symptoms and decrease the risk of cardiovascular problems. They argue that the most important goal of medical treatment in patients with...

  • Sarpogrelate, a 5-HT2A receptor antagonist in intermittent claudication. A Phase II European study. Norgren, L; Jawien, A; Mátyás, L; Rieger, H; Arita, K; The European MCI-9042 Study Group // Vascular Medicine;2006, Vol. 11 Issue 2, p75 

    This was a multinational, multicentre, double-blind Phase II study in Europe to evaluate the efficacy and safety of two dose regimens (200 mg bid and 200 mg tid) of sarpogrelate (MCI-9042, 5-HT2A receptor antagonist) compared to placebo in patients with stable, moderately severe intermittent...

  • A Double-Blind, Placebo-Controlled Study of the Effects of Policosanol in Patients with Intermittent Claudication. Castaño, Gladys; Más, Rosa; Roca, Juan; Fernández, Lilia; Illnait, José; Fernandez, Julio César; Selman, Eugenio // Angiology;Feb1999, Vol. 50 Issue 2, p123 

    This study was undertaken to evaluate the efficacy and tolerability of policosanol, a new cholesterol-lowering drug with concomitant antiplatelet effects, in patients with intermittent claudication. After a baseline period of 6 weeks, 62 patients were randomized to receive, under double-blind...

  • Leg Blood Flow in Intermittent Claudication -- A Comparison Between Non Insulin Dependent Diabetics and Non Diabetics. Janzon, Lars; Bergentz, Sven-Erik; Ericsson, Bjorn F.; Hanson, Martin; Lindell, Sven-Eric // Angiology;Nov1984, Vol. 35 Issue 11, p724 

    The influence of diabetes on leg blood flow in intermittent claudication has been assessed by comparing the systolic arm-ankle pressure gradient at rest and resistance to blood flow during reactive hyperemia in patients with non-insulin dependent diabetes and non-diabetic controls. Cases and...

  • Calf Blood Flow and Ankle Systolic Blood Pressure in Intermittent Claudication Monitored Over Five Years. Hutchison, K. J.; Williams, H. T. G.; Edmonton, C. H. B. // Angiology;Oct1978, Vol. 29 Issue 10, p719 

    The response of call blood flow and ankle blood pressure to 2 minutes of ischemic exercise were recorded every 6 months over a 5-year period in 9 patients with intermittent claudication who were treated conservatively on a regime including alpha tocopherol. No statistically significant change...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics